Market News

Baxter International (BAX)

Baxter announced that it has declared a quarterly dividend of $0.29 per Company common share.
This represents an increase of approximately 12% over the previous quarterly rate of $0.26 per share. The dividend is payable on January 5, 2010, to shareholders of record as of the close of business on December 10, 2009.

Nov 12 · 4:35:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

Abbott Laboratories announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF).
PG110 is a biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. NGF is released at sites of tissue damage and inflammation, and plays a significant role in the transmission of pain signals by the central nervous system.

Nov 12 · 1:53:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

The law firm Arnold & Itkin LLP has filed five lawsuits against the makers of pain pumps and related medications, including Abbott Labs, based on claims that many of the companies' defective devices are causing irreversible shoulder damage among patients. Currently, the attorneys at Arnold & Itkin are representing 28 people who received pain pumps to manage pain following shoulder surgery.
According to the lawsuits, pain pump manufacturers were denied approval by the U.S. Food and Drug Administration to use the pumps to mitigate pain in shoulder joints, but the companies continued to promote their use in that way. Many former pain pump users say the companies were negligent in designing, researching and selling pain pumps that they should have known were dangerous.

Nov 12 · 1:51:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

The U.S. Justice Department is investigating Abbott Laboratories' sales and marketing activities for its anti-seizure drug Depakote, the drug maker disclosed.
Abbott said in a regulatory filing that the U.S. Attorney for the Western District of Virginia is seeking to determine whether Abbott's marketing activities violated civil or criminal laws including the Federal False Claims Act, the Food and Drug Cosmetic Act, and the Anti-Kickback Statute "in connection with Medicare and/or Medicaid reimbursement to third parties."

Nov 11 · 3:23:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Pfizer (PFE)

Pfizer said Monday it will cease research-and-development activities in Research Triangle Park and Sanford as part of a major restructuring. The announcement comes less than three weeks after the pharmaceutical giant officially brought Wyeth into the fold. The restructuring will trim the number of R&D sites at Pfizer to five main locations and nine specialized units, down from 20 sites at the close of the Wyeth deal Oct. 16.

Nov 9 · 7:24:00 PM · Source: Triangle Business Journal
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Amgen (AMGN)

Amgen announced that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.

Nov 5 · 3:29:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Gilead Sciences (GILD)

Gilead Sciences today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
These new data show that the majority of patients who received Viread for up to 144 weeks experienced sustained suppression of HBV DNA levels in the blood to below 400 copies/mL (87 percent in Study 102 and 71 percent in Study 103). Additionally, cumulatively over 144 weeks, 8 percent of all patients in Study 103 (HBeAg-positive) experienced “s” antigen (HBsAg) loss, which can contribute to resolution of chronic hepatitis B infection. Notably, no mutations associated with resistance to Viread developed in any patients up to 144 weeks of treatment.

Nov 5 · 1:02:00 PM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

IMS Health (RX)

IMS Health announced Thursday it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital and the CPP Investment Board in a transaction with a total value of $5.2 billion, including the assumption of debt.

Nov 5 · 11:54:00 AM · Source: Company News
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Previous · Next